^
    PIK3CA V955G
    Colorectal Adenocarcinoma
    cetuximab
    Resistant: C3 – Early Trials
    ALK fusion
    Colorectal Adenocarcinoma
    ceritinib
    Sensitive: C3 – Early Trials
    KRAS mutation
    Colorectal Adenocarcinoma
    ceritinib
    Resistant: C3 – Early Trials
    EWSR1 mutation
    Colorectal Adenocarcinoma
    sintilimab + fruquintinib
    Resistant: C3 – Early Trials
    PD-L2 overexpression
    Colorectal Adenocarcinoma
    PD-L1 inhibitor + PD-L2 inhibitor
    Sensitive: D – Preclinical
    KRAS G13D
    Colorectal Adenocarcinoma
    ASN007
    Sensitive: D – Preclinical